Clinical data
AHFS/ Monograph
MedlinePlus a608003
ATC code L02BA02 (WHO)
Pharmacokinetic data
Protein binding more than 99.5%
Biological half-life 5 days
CAS Number 89778-26-7 YesY
PubChem (CID) 3005573
DrugBank DB00539 YesY
ChemSpider 2275722 YesY
KEGG D08620 YesY
PDB ligand ID T0R (PDBe, RCSB PDB)
ECHA InfoCard 100.125.139
Chemical and physical data
Formula C26H28ClNO
Molar mass 405.959 g/mol
3D model (Jmol) Interactive image

Toremifene citrate (/ˈtɔərmfin/) is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.[1]

In 2007 the pharmaceutical company GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008[2]

An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009,[3] and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial.[4]


  1. Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer 2005;3:211-4. PMID 15882476
  2. "GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review" (Press release). GTx Inc. 2007-07-12. Retrieved 2006-07-14.
  3. "GTx Announces Toremifene 80 mg NDA Accepted for Review by FDA" (Press release).
  4. "GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study". 2 Mar 2011.

This article is issued from Wikipedia - version of the 8/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.